PHARMACEUTICAL MARKET RESEARCH REPORTS
Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of BioProcess Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.
ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.
TRENDS AND MARKET OUTLOOKS
Central Lab Benchmarking & Market Dynamics (2nd Ed.)
This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.
Emerging Biopharma Perspective On Highly Potent API Manufacturing Market
An overview of the current market dynamics for high containment manufacturing from the perspective of HPAPI manufacturing decision-makers at sponsor organizations at small and midsize biopharmaceutical companies and their predictions on what the market will look like in five years.
Bioprocessing Market Outlook: 2022-2027
This report provides an overview of the current market dynamics for bioprocessing and predictions on its next five years. It also offers insight into the CDMO selection process and the main drivers of sponsor satisfaction on outsourced bioprocessing projects.
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)
This market research report goes into depth on the manufacturing aspect of biosimilars. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom.
Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)
This report explores which delivery formats drug innovators are using in their pipelines and portfolios, how likely innovators are to outsource manufacturing based on delivery device, and how these proportions will shift over the next five years.
Pharmaceutical Excipient Market Overview and Outlook
This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.
Development vs Commercial Outsourced Manufacturing Practices: Biologics
This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.
QUALITY BENCHMARKING AND SERVICE PROVIDER PERFORMANCE
Biologic API CDMO Benchmarking (8th Ed.)
This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CDMO service quality.
Biologic Drug Product CDMO Benchmarking (5th Ed.)
This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality.
Biologic API CDMO Benchmarking For New & Emerging Pharma
This report is based on responses from 45 people involved in outsourced large molecule API projects over the last 18 months. It will help new/emerging pharma companies make informed CDMO selections, and help CDMOs better understand how they are perceived.
Bioanalytical Labs Market Dynamics and Service Provider Performance
Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.
DEPARTMENT MODELS AND STRUCTURES
The CMC Function: Best Practices and Optimization
ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.
Understanding The Art And Science Of Patient Recruitment
As clinical trials become increasingly complex, it is more important than ever to understand how to overcome patient recruitment challenges in order to accelerate timelines, lower costs, and improve the quality of clinical trial data.
Five Steps To CDMO Selection
How to establish a plan that identifies outsourcing drivers, select a model that matches company needs and resources, establish a decision-making process and group, and designate key selection criteria.
Where Bioprocessing Outsourcers Stand On Capacity Concerns
Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.
Industry Trends: CDMO Outsourcing
No single CDMO strategy or outsourcing model is appropriate for every project. Outsourcers can and should evaluate a strategy and partner(s) on a case-by-case basis.
Small Molecule Drug Substance Outsourcing Drivers
ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).